Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment.
Schultheis
Beate
B
Szydlo
Richard
R
Mahon
François X
FX
Apperley
Jane F
JF
Melo
Junia V
JV
D018952:Antigens, CD34 / Q000096:biosynthesis*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D049109:Cell Proliferation; D015925:Cryopreservation; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D006801:Humans; D000068877:Imatinib Mesylate; D018189:Immunomagnetic Separation / Q000379:methods*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000276:immunology; D019000:Phosphotyrosine / Q000737:chemistry; D010865:Pilot Projects; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D015203:Reproducibility of Results; D013997:Time Factors; D016896:Treatment Outcome
D018952:Antigens, CD34; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D019000:Phosphotyrosine; D000068877:Imatinib Mesylate